- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04323748
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura (NYMC207)
The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.
Correlative studies will be performed as outlined in the appendices.
Quality of Life will be measured using the KIT as outlined in the protocol.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Erin Morris, RN
- Phone Number: 714-964-5359
- Email: erin_morris@nymc.edu
Study Contact Backup
- Name: Lauren Harrison, MSN
- Phone Number: 617-285-7844
- Email: lauren_harrison@nymc.edu
Study Locations
-
-
New York
-
Valhalla, New York, United States, 10595
- Recruiting
- New York Medical College
-
Contact:
- Jordan Milner, MD
-
Contact:
- Elizabeth Mintzer, CRA
- Email: emintzer2@nymc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: Subjects must be ≥ 1 year and ≤ 21 years of age.
- Diagnosis: Patients must have newly diagnosed ITP and a platelet count of ≤ 20 x 109 per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow.
High-risk features : In addition, patients must have one of more of the following high-risk criteria:
- Age ≥ 10 years
- Grade II-IV bleeding at diagnosis
- ANA positivity
- No history of preceding infection within 2 weeks prior to ITP diagnosis
- Performance Status: Patients must have a performance status ≥ 50%. Use Karnofsky for patients > 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
Prior Therapy
- Patients may not have received any treatment for ITP prior to start of therapy.
- Patients may not receive systemic steroids ≥ 0.5 mg/kg prednisone (or equivalent) within 2 weeks prior to diagnosis.
Concomitant Medications Restrictions:
- Steroids are only warranted as premedication prior to rituximab.
- Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol.
Organ Function Requirements
- Adequate Renal Function Defined As: estimated CrCl > 60 mL/min or >30% of GFR for age based on the Schwartz formula
- Adequate Liver Function Defined As: AST and/or ALT less than 5 times the upper limit of normal, and/or direct bilirubin less than the 2 times of the upper limit of normal
Exclusion Criteria
- Patients with a history of Grade III-IV allergic reaction to rituximab
- Patients with bone marrow neoplastic infiltration
- Patients with a history of hepatitis B infection
Pregnancy and Breast Feeding
- Female patients who are pregnant are ineligible (insert the reason: "due to risks of fetal and teratogenic adverse events as seen in animal/human studies" or "since there is yet no available information regarding human fetal or teratogenic toxicities").
- Lactating females are not eligible unless they have agreed not to breastfeed their infants.
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rituximab
All patients enrolled will receive the dose dense administration of rituximab.
Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
|
The dose dense administration of rituximab will consist of 5 doses total Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety events: Number of participants with treatment-related Grade III or higher adverse events as assessed by CTCAE v5.0.
Time Frame: 1 year
|
To determine the occurrence of any Grade ≥ 3 non hematologic toxicity (per CTCAE v.5) which is possibly, probably, or definitely related to rituximab.
|
1 year
|
To determine the Response Rate
Time Frame: 1 year
|
To quantify remission rates for high-risk patients with acute ITP treated with a dose dense administration of rituximab.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jordan Milner, MD, New York Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- 14124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenic Purpura
-
Harbour BioMed (Guangzhou) Co. Ltd.RecruitingPrimary Immune Thrombocytopenic PurpuraChina
-
Novartis PharmaceuticalsCompletedImmune Thrombocytopenic Purpura (ITP)Spain, Italy, Greece, Switzerland, United Kingdom, France, Turkey, Russian Federation, Brazil, Austria, Mexico, Oman, Chile, Japan, United States
-
Institute of Hematology & Blood Diseases HospitalRecruitingPrimary Immune Thrombocytopenic PurpuraChina
-
Momenta Pharmaceuticals, Inc.TerminatedImmune Thrombocytopenic Purpura (ITP)United States, Poland, Hungary, Netherlands, Italy, Spain, Belgium
-
National Institute of Blood and Marrow Transplant...NovartisUnknownImmune Thrombocytopenic Purpura (ITP)Pakistan
-
Instituto Grifols, S.A.CompletedImmune (Idiopathic) Thrombocytopenic PurpuraSpain, Russian Federation, United Kingdom
-
AmgenCompletedThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic PurpuraUnited States, Canada, Australia
-
David Gomez AlmaguerUnknownThrombotic Thrombocytopenic Purpura | Immune ThrombocytopeniaMexico
-
Neufeld, Ellis J, MD, PhDGenentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...CompletedImmune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)United States
-
Anthera PharmaceuticalsWithdrawnIdiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Clinical Trials on rituxan
-
University of VermontGenentech, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...Completed
-
Georgetown UniversityHackensack Meridian HealthActive, not recruitingChronic Lymphocytic LeukemiaUnited States
-
Hangzhou DAC Biotechnology Co., Ltd.Not yet recruitingAdvanced Solid Tumors | Hematological Malignancies
-
German Parkinson Study Group (GPS)Philipps University Marburg Medical Center; MSE Pharmazeutika GmbH, Louisenstr... and other collaboratorsCompletedProgressive Supranuclear PalsyGermany
-
Massachusetts General HospitalGenentech, Inc.WithdrawnKidney Insufficiency | Chronic Rejection
-
Massachusetts General HospitalGenentech, Inc.; BiogenWithdrawn
-
Genentech, Inc.CompletedMicroscopic Polyangiitis | Granulomatosis With PolyangiitisUnited States
-
Johns Hopkins UniversityCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Massachusetts General HospitalGenentech, Inc.CompletedSialadenitis | Retroperitoneal Fibrosis | Autoimmune Pancreatitis | Pseudotumor